Julia Katharina Schwarze

13PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematological tumoursChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 26, 2026
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative Review.

|Jan 11, 2024
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.

Jens Tijtgat, Xenia Geeraerts, Anais Boisson

|Nov 08, 2023
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.

Víctor A Arrieta, Johnny Duerinck, Kirsten B Burdett

|Sep 16, 2022
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.

Julia Katharina Schwarze, Jens Tijtgat, Gil Awada

|Jul 06, 2022
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.

Prachi Bhave, Tasnia Ahmed, Serigne N Lo

|May 14, 2022
Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1+ Myeloid Dendritic Cells.

Philipp Kalus, Jolien De Munck, Sarah Vanbellingen

Pageof 3

Frequent Collaborators

12 joint publications

Bart Neyns

8 joint publications

Gil Awada

4 joint publications

Jens Tijtgat

3 joint publications

Sandra Tuyaerts